Perspective Therapeutics, Inc. has announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company’s ongoing Phase 1/2a study.

IDT announces a collaboration with Illumina to enable integrated oncology research workflows that combine IDT library preparation with DRAGEN™ secondary analysis, streamlining the path from sequencing to insight for somatic oncology research applications.

SunHydrogen has successfully installed hydrogen modules built with its latest design improvements at its pilot demonstration system at the University of Texas at Austin's Hydrogen ProtoHub.

Perspective Therapeutics, Inc. has announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively.

New Austrian entity deepens ties with Europe’s hydrogen ecosystem and complements the industrialization process of SunHydrogen’s development efforts in Coralville, Iowa.

IDT has expanded its Coralville manufacturing footprint, boosting synthesis capacity by threefold, to meet the rapidly growing demand for MRD and NGS-based oncology research workflows

The upcoming Artemis II mission will send astronauts around the moon, but future missions will put humans back on the lunar surface, where they'll need a vehicle.

New entity strengthens SunHydrogen’s ties with Japan’s leading solar hydrogen research community and gives an ongoing scientific collaboration a permanent structure.

IDT has launched its first in vitro diagnostic NGS assays—Archer FUSION Plex™‑HT Dx and VARIANT Plex™‑HT Dx—marking its entry into the clinical diagnostics market with standardized, IVD‑grade solutions for oncology workflows.